Abstract
The guidelines support healthcare professionals in pharmacotherapeutic decision-making, but do not replace individual actions that can be taken for specific patients. This guideline aims to harmonize the pharmacological treatment of metastatic non-small cell lung cancer (PCNM) and is aimed primarily at health professionals related to medical oncology and directly to this pathology. Its recommendations consider in terms of population, the criteria of effectiveness, safety, efficiency and sustainability of health care to ensure universal accessibility and equity.
Keywords
Metastatic non-microcytic lung cancer; Immunotherapy; Targeted therapy
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Pautes per a l'harmonització del tractament farmacoterapèutic del càncer de pulmó no microcític metastàtic. Barcelona: Servei Català de la Salut; 2021.